Regular ArticleThe Decreased in Vivo Clearance of CYP2D6 Substrates by CYP2D6*10 Might Be Caused Not Only by the Low-Expression but Also by Low Affinity of CYP2D6
References (32)
- et al.
Trends Pharmacol. Sci.
(1992) - et al.
Biochem. Pharmacol.
(1996) - et al.
Arch. Biochem. Biophys.
(1996) - et al.
Arch. Biochem. Biophys.
(1995) - et al.
J. Biol. Chem.
(1992) - et al.
Genomics
(1988) - et al.
Arch. Biochem. Biophys.
(1997) - et al.
Biochim. Biophys. Acta
(1993) - et al.
Arch. Biochem. Biophys.
(1990) - et al.
J. Biol. Chem.
(1964)
J. Biol. Chem.
(1951)
J. Biol. Chem.
(1976)
Pharmacogenetics
(1996)
DNA Cell Biol.
(1991)
Clin. Pharmacol. Ther.
(1989)
Cited by (79)
Is CYP2D6 phenotype predictable from CYP2D6 genotype?
2018, Microchemical JournalCitation Excerpt :CYP2D6*10 has a 100C > T SNP leading to the instability of the enzyme protein [11]. CYP2D6*41 contains an intronic 2988G > A SNP causing increased levels of a non-functional splice variant and accordingly lower CYP2D6 metabolic activity [12]. CYP2D6*41 frequently occurs in Caucasians (allele frequency: 7–10%) [13].
Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity
2014, Drug Metabolism and PharmacokineticsIn vitro assessment of the allelic variants of cytochrome P450
2012, Drug Metabolism and PharmacokineticsRole of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B
2022, Drug metabolism and bioanalysis lettersSubstrate specificity of CYP2D6 genetic variants
2021, PharmacogenomicsChallenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications
2019, Pharmacogenomics Journal
- 1
To whom correspondence should be addressed. Fax: +81-6-6879-8259. E-mail: [email protected].
Copyright © 2000 Academic Press. All rights reserved.